KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.
There’s no fine print—it’s all here in black and white.
Consistently superior overall survival in two phase III trials. Only one CDK4/6 inhibitor is able to say this—KISQALI
Superior overall survival was proven in MONALEESA-3 and MONALEESA-7.1,2See the consistent OS benefit
about the OS data
References: 1. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer [published online December 11, 2019]. N Engl J Med. doi:10.1056/NEJMoa1911149. 2. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316(suppl).